Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

BACKGROUND: Pragmatic use of the anti-fibrotic medications pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF) in the United States (US) has not been studied and may be different from international settings due to structural differences between health care systems. This study examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Holtze, Colin H., Freiheit, Elizabeth A., Limb, Susan L., Stauffer, John L., Raimundo, Karina, Pan, Wayne T., Flaherty, Kevin R., Kim, Hyun J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011239/
https://www.ncbi.nlm.nih.gov/pubmed/32041621
http://dx.doi.org/10.1186/s12931-020-1315-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011239/
https://www.ncbi.nlm.nih.gov/pubmed/32041621
http://dx.doi.org/10.1186/s12931-020-1315-4

Ejemplares similares